

## Laurence Chen

PATENT AGENT

Patents and  
Innovations  
San Francisco

laurence.chen@wsgr.com  
212-497-7743

### FOCUS AREAS

Biotech  
Clean Energy  
FoodTech and AgTech  
Intellectual Property  
Life Sciences  
Medical Devices  
Patents and Innovations

### EXPERIENCE

Dr. Laurence Chen is a patent agent in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm's patents and innovations practice. His technical expertise spans a variety of fields including biological engineering, gene editing, cancer immunotherapy, and multi-omic technologies.

Prior to joining the firm, Laurence completed his doctorate degree in chemical engineering at the University of California, Los Angeles. His doctoral research leveraged synthetic biology, protein engineering, cell engineering, and multi-omics in developing CAR-T cells for next-generation cancer immunotherapies. His graduate work has resulted in multiple scientific publications and he is also a co-inventor on multiple patent applications.

### CREDENTIALS

#### Education

- Ph.D., Chemical Engineering, University of California, Los Angeles, 2022
- B.S., Bioengineering: Biotechnology, University of California, San Diego, 2016

#### Admissions

- U.S. Patent and Trademark Office

### INSIGHTS

#### Select Publications

- Co-lead author with X. Chen and Y.Y. Chen, "Rational protein design yields a CD20 CAR with superior antitumor efficacy compared to CD19 CAR," *Cancer Immunology Research*, 2022
- Co-author with A. Lakhani, Y.Y. Chen, and J.O. Park, "Extracellular domains of CARs reprogramme T cell metabolism without antigen stimulation," *Nature Metabolism*, 2024
- Co-lead author with A.J. Hou and Y.Y. Chen, "Navigating CAR-T cells through the solid-tumour microenvironment," *Nature Reviews Drug Discovery*, 2021
- Lead author with Y.Y. Chen, "Bacteria recycle tumour waste to fuel immune cells," *Nature (News & Views)*, 2021
- Lead author with Y.Y. Chen, "Outsmarting and outmuscling cancer cells with synthetic and systems immunology," *Current Opinion in Biotechnology*, 2019

### TECHNICAL FLUENCY

#### Biological Sciences and Biotechnology

- Antibody

- Antigen presentation
- Biochemical assays
- Biochemistry
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell culture products
- Cell therapy
- Cellular biology
- Cellular immunology
- Immuno-oncology
- Immunobiology
- Immunology
- Molecular biology
- Molecular genetics
- PCR
- T cell biology
- T cell immunology

## **Therapeutics and Drug Discovery**

- CRISPR
- Gene editing
- Gene therapy
- Immunotherapy targets
- Peptide therapeutics

## **Diagnostics and Medical Devices**

- Biomedical engineering

## **Chemistry and Material Science**

- Protein engineering

## **Engineering and Technology**

- 3D bioprinting

## **Genomics and Data Analysis**

- Bioinformatics algorithms
- Computational biology
- Next-generation sequencing
- Single-cell sequencing

## **Miscellaneous**

- Cancer
- Engineered foods
- Food science